- Home
- BRW vs CRMD Comparison
BRW vs CRMD Comparison
Compare BRW & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRW
- CRMD
- Stock Information
- Founded
- BRW 1987
- CRMD 2006
- Country
- BRW United States
- CRMD United States
- Employees
- BRW N/A
- CRMD N/A
- Industry
- BRW Trusts Except Educational Religious and Charitable
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- BRW Finance
- CRMD Health Care
- Exchange
- BRW Nasdaq
- CRMD Nasdaq
- Market Cap
- BRW 333.0M
- CRMD 877.5M
- IPO Year
- BRW N/A
- CRMD 2010
- Fundamental
- Price
- BRW $8.12
- CRMD $11.28
- Analyst Decision
- BRW
- CRMD Strong Buy
- Analyst Count
- BRW 0
- CRMD 7
- Target Price
- BRW N/A
- CRMD $17.33
- AVG Volume (30 Days)
- BRW 222.1K
- CRMD 2.2M
- Earning Date
- BRW 01-01-0001
- CRMD 08-13-2025
- Dividend Yield
- BRW 15.59%
- CRMD N/A
- EPS Growth
- BRW N/A
- CRMD N/A
- EPS
- BRW N/A
- CRMD 0.28
- Revenue
- BRW N/A
- CRMD $82,553,827.00
- Revenue This Year
- BRW N/A
- CRMD $238.38
- Revenue Next Year
- BRW N/A
- CRMD $53.52
- P/E Ratio
- BRW N/A
- CRMD $40.46
- Revenue Growth
- BRW N/A
- CRMD N/A
- 52 Week Low
- BRW $7.15
- CRMD $3.61
- 52 Week High
- BRW $8.30
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- BRW 65.91
- CRMD 39.54
- Support Level
- BRW $8.06
- CRMD $11.13
- Resistance Level
- BRW $8.18
- CRMD $11.86
- Average True Range (ATR)
- BRW 0.08
- CRMD 0.65
- MACD
- BRW 0.00
- CRMD -0.34
- Stochastic Oscillator
- BRW 82.86
- CRMD 3.81
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.